Harmful effects of viral replication in seropositive hepatitis c virus renal transplant recipients

Transplantation

Volumn 94, Issue 11, 2012, Pages 1131-1137

  Govantes, Miguel A Gentil ^a   Esforzado, Núria ^b   Cruzado, Josep M ^c   González Roncero, Francisco M ^a   Balaña, Montserrat ^d   Saval, Núria ^d   Morales, José M ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d Health Outcomes Research   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Active viremia; Hepatitis C virus; Reactivation; Renal transplantation; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAZARD RATIO; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN; SURVIVAL PREDICTION; TREATMENT OUTCOME; TREND STUDY; VIREMIA; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SPAIN; TIME FACTORS; TRANSAMINASES; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

EID: 84871620555     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826fc98f     Document Type: Article

References (35)

1. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19(suppl 3): iii72.
2. Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol 2002; 22: 365.
3. Pereira BJ. Hepatitis C in organ transplantation: its significance and influence on transplantation policies. Curr Opin Nephrol Hypertens 1993; 2: 912.
4. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152.
5. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of Hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 73(suppl 109): S1.
6. Covic A, Abramowicz D, Bruchfeld A, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009; 24: 719.
7. Morales JM, Marcen R, Andres A, et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus 2010; 3(suppl 2): ii41.
8. Gentil MA, Rocha JL, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455.
9. Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452.
10. Rostami Z, Nourbala MH, Alavian SM, et al. The impact of hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: the impact of HCV on renal transplantation. Hepat Mon 2011; 11: 247.
11. López-Medrano F, Fernández-Ruiz M, Morales JM, et al. Spanish Network for the Research of Infection in Transplantation/Network of Research in Infectious Diseases (RESITRA/REIPI) Study Group. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. Transplantation 2011; 92: 543.
12. Kimball P, Verbeke S, Shiffman M. HCV core protein augments cy-closporine immunosuppression. Transplant Proc 2005; 37: 652.
13. Seth AK, Anand AC, Gedela SR, et al. Rapid progression of hepatitis CYinduced liver failure in renal allograft recipients. Indian J Gastro-enterol 2006; 25: 155.
14. Mas V, Alvarellos T, Chiurchiu C, et al. Hepatitis C virus infection after renal transplantation: viral load and outcome. Transplant Proc 2001; 33: 1791.
15. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virusYrelated liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704.
16. Cosio FG, Sedmak DD, Henry ML, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054.
17. Baid S, Pascual M, Williams WW, et al. Renal thrombotic micro-angiopathy associated with anticardiolipin antibodies in hepatitis CYpositive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146.
18. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virusYinfected renal allograft recipients. Transplantation 1995; 59:1676.
19. Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virusYassociated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469.
20. Baid-Agrawal S, Farris AB III, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879.
21. Ozdemir BH, Bilezikci B, Haberal M. Hepatic stellate cells in hepatitis C patients: relationship with the development of interstitial fibrosis in renal allografts. Transplant Proc 2009; 41: 2838.
22. Pawlak K, Mysliwiec M, Pawlak D. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas-the new putative determinants of endothelial dysfunction in haemodialysis patients. Thromb Res 2010; 126: 393.
23. Fabrizi F, Lunghi G, Dixit V, et al. Meta-analysis: anti-viral therapy of hepatitis C virusYrelated liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413.
24. Dominguez-Gil B, Esforzado N, Munoz MA, et al. Renal transplantation using kidneys from donors with hepatitis C virus positive se-rology. Nefrologia 2001; 21(suppl 4): 119.
25. Morales JM, Andres A, Campistol JM. Hepatitis C virus and organ transplantation. N Engl J Med 1993; 328: 511.
26. Morales JM, Campistol JM, Dominguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis CYpositive donors into hepatitis CYpositive recipients. Am J Transplant 2010; 10: 2453.
27. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72: 241.
28. Cruzado JM, Torras J, Gil-Vernet S, et al. Glomerulonephritis associated with hepatitis C virus infection after renal transplantation. Nephrol Dial Transplant 2000; 15(suppl 8): 65.
29. Morales JM, Campistol JM, Andres A, et al. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511.
30. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: sub-clinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
31. Hestin D, Guillemin F, Castin N, et al. Pre-transplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 1998; 65: 741.
32. Mahmoud IM, Elhabashi AF, Elsawy E, et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43: 131.
33. Melon S, Galarraga MC, Villar M, et al. Hepatitis C virus reactivation in anti-hepatitic C virusYpositive renal transplant recipients. Transplant Proc 2005; 37: 2083.
34. Gordon CE, Uhlig K, Schmid CH, et al. Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialy-sis. Clin J Am Soc Nephrol 2011; 6: 2226.
35. Cruzado JM, Casanovas-Taltabull T, Torras J, et al. Pretransplant in-terferon prevents hepatitis C virusYassociated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357.